GH Research (GHRS) Free Cash Flow (2020 - 2025)
GH Research (GHRS) posted quarterly Free Cash Flow of -$12.3 million for Q4 2025, down 18.14% year-over-year from -$15.0 million in Q4 2024, and up 9.76% quarter-over-quarter from -$13.6 million in Q3 2025.
GH Research (GHRS) Free Cash Flow (2020 - 2025) Analysis & Trends
GH Research's Free Cash Flow history runs 6 years deep, the most recent figure standing at -$12.3 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 18.14% year-over-year to -$12.3 million; the TTM figure through Dec 2025 stood at -$43.4 million (down 2.83% YoY), while the FY2025 annual figure was -$43.4 million, down 2.83% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$12.3 million, up from -$13.6 million in the prior quarter.
- The five-year high for Free Cash Flow was -$1.1 million in Q1 2021, with the low at -$13.6 million in Q3 2025.
- The 5-year median for Free Cash Flow is -$8.7 million (2025), against an average of -$8.2 million.
- The sharpest annual moves came in 2021 and 2024: Free Cash Flow slumped 11800.0% in 2021, then increased 12.4% in 2024.
- GH Research's Free Cash Flow stood at -$3.9 million in 2021, then sank by 89.03% to -$7.5 million in 2022, then tumbled by 59.44% to -$11.9 million in 2023, then grew by 12.4% to -$10.4 million in 2024, then declined by 18.14% to -$12.3 million in 2025.
- Business Quant data shows GHRS's Free Cash Flow at -$12.3 million in Q4 2025, -$13.6 million in Q3 2025, and -$8.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.31 Mn |
| Dec 31, 2025 | -12.31 Mn |
| Sep 30, 2025 | -13.64 Mn |
| Sep 30, 2025 | -13.64 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Dec 31, 2024 | -10.42 Mn |
| Dec 31, 2024 | -10.42 Mn |
| Sep 30, 2024 | -12.30 Mn |
| Sep 30, 2024 | -12.30 Mn |
| Jun 30, 2024 | -9.93 Mn |
| Jun 30, 2024 | -9.93 Mn |
| Mar 31, 2024 | -9.58 Mn |
| Mar 31, 2024 | -9.58 Mn |
| Dec 31, 2023 | -11.90 Mn |
| Dec 31, 2023 | -11.90 Mn |
| Sep 30, 2023 | -10.33 Mn |
| Sep 30, 2023 | -10.33 Mn |